Hemato Oncology Testing Market Size, Share & Trends Analysis Report By Product (Assay Kits & Reagents, Services), By Cancer Type (Leukemia, Lymphoma, MPNs), By Technology, By End-use, By Region, And Segment Forecasts, 2020 - 2027

Report Overview

The global hemato oncology testing market size was estimated at USD 2.5 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 14.6% from 2020 to 2027. Hemato oncology is typically referred to as the science associated with the treatment, diagnosis, and prevention of blood-related diseases and cancers. The rising prevalence of lymphoma and myeloma is anticipated to propel the growth of the market during the forecast period. According to the American Cancer Society, Non-Hodgkin Lymphoma (NHL) is estimated to be one of the most common forms of cancer in the U.S., accounting for nearly 4.0% of all cancers in the country. An estimated 74,200 individuals, inclusive of 41,090 men and 33,110 women, were diagnosed with NHL in 2019.

Similarly, data from the National Cancer Institute indicates that around 21,450 cases of acute myeloid leukemia were observed in 2019 in the U.S. The number of acute myeloid leukemia cases was 4.3 per 100,000 women and men per year as estimated by the same source. Therefore, a rise in the prevalence of blood cancer is expected to boost hemato oncology testing during the forecast period. 

The proliferation of sequencing techniques such as NGS due to the increasing cost of development and sequencing of the Human Genome Project in the field of genomics is expected to fuel the growth of the market. Major companies in the personalized medicine market space are typically involved in multiple investment programs about precision medicine. In addition, companies provide various molecular decision support systems that combine genomic and clinical data in order to reduce the gaps in precision medicine practice.

In addition, a recent research study conducted by Bloodwise in 2018, a blood cancer research charity team, indicated positive results for the research study, which is anticipated to facilitate the use of personalized medicine for the treatment of Acute Myeloid Leukemia (AML) in the near future.

The rise in the availability of advanced molecular techniques for the diagnosis of hemato oncology is also one of the major factors contributing to the growth of the market for hemato oncology testing. The introduction of advanced molecular techniques has been pivotal in addressing concerns pertaining to blood cancer prognosis, treatment course, and diagnosis. For instance, immunophenotyping relies on the evaluation of leukocyte cancer cells and aids in the characterization of cancer type. Chronic myeloid leukemia can also be diagnosed with the usage of various cytogenetic techniques such as PCR that targets ABL/BCR genes or FISH.

An increase in the co-development of the drug-diagnostics model is also expected to fuel the growth of the market during the forecast period. For instance, the first companion diagnostic used for the detection of Acute Myeloid Leukemia was CE approved in 2017. Also, the FDA approval of Invivoscribe’s LeukoStrat companion diagnostic test in conjugation with Novartis’s Rydapt for detection and treatment of AML has been key in the rising number of manufacturers opting for the development of related products.

Product Insights

The services segment dominated the hemato oncology testing market and accounted for the largest revenue share of 57.3% in 2019 due to the growing incidence of non-Hodgkin lymphoma, myeloma, and leukemia. Rising awareness regarding various treatment therapies such as personalized medicines is also anticipated to drive segment growth during the forecast period.

Also, in July 2019, the academic hematology department of the Erasmus Medical Center was one of the first hospitals worldwide that offered each multiple myeloma patients a novel diagnostic testing service. This service helps the healthcare professional to predict the aggressiveness of myeloma by measuring over 92 genes in the various cancer cells. Thus, a rise in the availability of services offered for the diagnosis of myeloma is expected to boost the growth of the market during the forecast period.

The rise in the development of new tests for the diagnosis of myeloma is also a major factor anticipated to fuel the growth of the market during the forecast period. For instance, in November 2019, scientists from the University of Toronto collaborated with scientists from China in order to develop a new blood test for the detection of myeloma that is easier and more reliable than the other available tests.

Also, in June 2017, the U.S. FDA permitted Beckman Coulter to market its ClearLLab Reagents used for the detection of various lymphomas and leukemia. These reagents include ClearLLab B1, ClearLLab T1, ClearLLab M, and ClearLLab T2. The company received permission to market these reagents on a flow cytometry-based test for the detection of cancers such as acute and chronic leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, and myeloma.

Technology Insights

The PCR segment dominated the market and held the largest revenue share of 32.5% in 2019. This is owing to its ease in use, affordability, accuracy and efficiency provided, and easy availability. In July 2018, the BloodCenter of Wisconsin’s Diagnostic Laboratories announced the launch of Abbott’s RealTime IDH1 assay. This is a PCR test that is highly sensitive in detecting IDH1 genetic mutations that are found in patients’ bone marrow and blood samples. Therefore, an increase in the launch of PCR based tests is expected to fuel the growth of the market during the forecast period.

Similarly, in October 2019, Cepheid’s Xpert BCR-ABL Ultra received FDA clearance for monitoring the burden of chronic myeloid leukemia in individuals. This is an in-vitro diagnostic test and also helps to deliver accurate results from whole blood samples collected within 3 hours. The product helps in measuring the level of BCR-ABL gene transcript that in order helps in indicating the rate of progress of the treatment and also predicts relapses. Thus, a rise in product approvals is expected to fuel the adoption of hemato oncology testing products.

The rise in the number of research studies conducted by various academic and research institutes to develop genetic testing for various blood cancers is anticipated to fuel the growth of the market during the forecast period. For instance, in September 2018, the Myeloma U.K. funded a research study that used genetic testing for the detection of myeloma. The study aims at increasing the understanding related to the complex genetics that underpins myeloma. This study can be used to form new treatment options that show quicker results.

The NGS segment is expected to witness the fastest growth during the forecast period due to various advantages offered by this technology such as more sensitivity and specificity. For instance, in September 2018, the U.S. FDA permitted the marketing of ClonoSEQ assay, an NGS-based test used to detect low levels of cancer cells remaining in patients diagnosed with multiple myeloma or lymphoblastic leukemia. Thus, a growing number of FDA approvals for NGS-based tests is also anticipated to boost the growth of the market.

End-use Insights

Hospitals led the market and accounted for more than 74.5% revenue share in 2019. The witnessed growth is due to the various diagnostic tests provided, the rise in the incidence rate of blood cancers, availability of specialized laboratory settings, and the presence of healthcare professionals to conduct diagnostic tests, and monitor the disease.

Besides, the academic and research institutes segment also accounted for a considerable share due to the presence of academic groups that conduct various studies and researches to enhance the field of hemato oncology. Benefits such as a greater understanding of the diagnostic procedure and availability of technologically advanced products for diagnosis are anticipated to exhibit exponential growth opportunities in the market.

Growth in the number of research activities conducted by various academic and research institutes is also one of the major factors responsible for the growth of the market during the forecast period. For instance, in July 2018, researchers from the University of Kansas have developed a reliable, reusable, and low-cost blood test that utilizes a small plastic chip to diagnose as well as monitor multiple myeloma. This study was funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB).

Cancer Type Insights

The lymphoma segment dominated the market and held the largest revenue share of 46.1% in 2019. This is due to the rise in the prevalence of Non-Hodgkin and Hodgkin Lymphoma. As per the U.S. National Institutes of Health (NIH) in 2019, NHL is the seventh most common cancer in the U.S., representing 4.2% of all cancers in the nation. In addition, the median age of people most commonly diagnosed with NHL is 67 years. Similarly, data from Cancer Research UK indicates that the incidence of NHL is rising, with 13,900 new cases of NHL being diagnosed each year in the U.K. NHL is the sixth most common type of cancer in the region, accounting for 4% of all new cases. The incidence of NHL has increased to 39% in the U.K. since the early 1990s. Thus, various private and public organizations are undertaking initiatives to enhance awareness among individuals globally. For instance, the Leukaemia Foundation provides a toolkit of resources that enhance the spreading of blood cancer awareness among individuals.

Multiple myeloma is a rather uncommon cancer with an estimated lifetime risk at 0.76% or 1 in 132 individuals in the U. S. According to the American Cancer Society, approximately 32,110 people were estimated to be diagnosed with multiple myeloma and 12,960 deaths were expected to occur due to the disease in 2019. Thus, as there are no symptoms of cancer until the last stage, early detection remains an issue, thereby urging various manufacturers to develop tests that aid in the early detection of cancer. 

A rise in the availability of technologically advanced products for the diagnosis of acute myeloid leukemia is also anticipated to fuel the growth of the market during the forecast period. For instance, in December 2019, researchers from the University of Bonn and the German center for neurodegenerative diseases led a research study using artificial intelligence to detect acute myeloid leukemia with higher reliability. This approach can be used along with conventional diagnostic techniques in order to accelerate the process.

Regional Insights

North America dominated the market and accounted for over 35.8% of revenue share in 2019. This growth is attributed to the rising incidence of leukemia, lymphoma, and multiple myeloma. In addition, supportive initiatives undertaken by major market players and various academic and research organizations are also driving the market. For instance, in October 2018, scientists from Dana-Farber Cancer Institute announced the launch of a screening study for individuals who are at a high risk of multiple myeloma. The study was funded by the “Stand Up To Cancer Multiple Myeloma Dream Team” to help scientists track molecular changes associated with myeloma.

Similarly, a rise in the prevalence of Hodgkin lymphoma is another major factor expected to fuel the growth of the market during the forecast period. According to the American Cancer Society, approximately 1.7 million new cancer cases were estimated to be diagnosed in 2019. Hodgkin lymphoma was also estimated to account for 0.2% of all cancer deaths in the same year. Furthermore, the survival rate for the disease is estimated to be 86.6% owing to the timely diagnosis and advent of novel therapies.

The growing incidence of multiple myeloma across Europe is also expected to fuel the growth of the market during the forecast period. According to a survey conducted by the WHO, an estimated 9,414, 16,830, 12,425, and 9,628 new myeloma cases were diagnosed in Central and Eastern Europe, Western Europe, Southern Europe, and Northern Europe respectively.

In Asia Pacific, the market is anticipated to witness the highest growth rate owing to an increase in the prevalence of blood cancer, and a growing number of research activities conducted by various academic research institutes. For instance, in August 2019, scientists from Monash University developed a novel blood test that helps in the detection of myeloma. This is a liquid biopsy test that is more accurate and is a less invasive alternative to the current bone marrow biopsy.

Key Companies & Market Share Insights 

A rise in collaborations among various market players is anticipated to fuel the growth of the market during the forecast period. For instance, in December 2019, Adaptive Biotechnologies collaborated with AbbVie for the use of Adaptive’s NGS based minimal residual disease testing in the drug trials of multiple myeloma. As per the agreement, AbbVie will utilize Adaptive’s clonoSEQ assay in order to access the MRD status across multiple clinical trials. The partners aim at evaluating the duration and depth of response to Venetoclax with the help of clonoSEQ in order to monitor and measure MRD negativity. Some of the prominent players in the hemato oncology testing market include:

• F. Hoffman-La Roche Ltd

• Abbott Laboratories

• EntroGen, Inc.

• Qiagen N.V.

• Cepheid

• Thermo Fisher Scientific, Inc.

• Bio-Rad Laboratories, Inc.

• Illumina, Inc.

Hemato Oncology Testing Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global hemato oncology testing market report on the basis of cancer type, product, technology, end-use, and region:

• Cancer Type Outlook (Revenue, USD Million, 2016 - 2027)

  • Leukemia

    • Acute Myeloid Leukemia (AML)

    • Acute Lymphocytic Leukemia (ALL)

    • Chronic Lymphocytic Leukemia

    • Chronic Myeloid Leukemia

  • Lymphoma

    • Non-Hodgkin Lymphoma

    • Hodgkin Lymphoma

  • Myeloproliferative Neoplasms

    • Polycythemia vera (PV)

    • Essential thrombocythemia (ET)

    • Myelofibrosis (MF)

  • Other Cancers

• Product Outlook (Revenue, USD Million, 2016 - 2027)

  • Assay Kits and Reagents

  • Services

• Technology Outlook (Revenue, USD Million, 2016 - 2027)

  • PCR

    • Real-time qPCR

    • Digital PCR

  • IHC

  • NGS

  • Cytogenetics

  • Other Technologies

• End-use Outlook (Revenue, USD Million, 2016 - 2027)

  • Hospitals

  • Academic & Research Institutes

  • Others

• Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America

    • Canada

    • U.S.

  • Europe

    • U.K.

    • Russia

    • Germany

    • France

    • Spain

    • Italy

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Singapore

  • Latin America

    • Mexico

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE